Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.85M 3.34M 3.13M 2.85M 368M 5.46M 36.66M 14.36M 184M 14.47M 14.15M 614M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.51M 3.91M 3.66M 3.34M 431M 6.39M 42.94M 16.83M 216M 16.95M 16.58M 719M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -1.48% | +0.82% | +3.66% | +14.53% | 49.54B | |
| -0.69% | +6.25% | +492.36% | +585.40% | 44.06B | |
| +0.08% | +11.23% | +23.99% | +81.74% | 40.85B | |
| +0.76% | +6.85% | +35.40% | +10.92% | 40.14B | |
| +4.73% | +13.29% | +27.76% | +54.22% | 34.17B | |
| +0.51% | +5.29% | +34.62% | +126.87% | 16.9B | |
| -0.41% | +4.08% | - | - | 16.78B | |
| -0.63% | -0.32% | +4.01% | +20.46% | 14B | |
| +1.81% | +20.45% | +89.35% | +31.49% | 13.46B | |
| Average | +1.72% | +7.75% | +88.90% | +115.70% | 29.99B | |
| Weighted average by Cap. | +0.63% | +7.39% | +106.93% | +138.26% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.23M -13.2M -12.35M -11.27M -1.45B -21.57M -145M -56.76M -727M -57.18M -55.93M -2.43B | 4.21M 3.02M 2.62M 2.45M 2.24M 288M 4.28M 28.75M 11.26M 144M 11.35M 11.1M 481M |
| Net Debt | 704K 505K 438K 410K 374K 48.2M 716K 4.81M 1.88M 24.13M 1.9M 1.86M 80.49M | 920K 660K 572K 536K 489K 62.99M 935K 6.28M 2.46M 31.53M 2.48M 2.43M 105M |
Employees
-
